Vessix Introduces a Faster, Easier Approach to Renal Denervation for Hypertension

Vessix's device, the V2 Renal Denervation System(tm) for the treatment of uncontrolled hypertension is an over-the-wire balloon catheter with electrodes mounted on the exterior of the balloon to facilitate the rapid delivery of precise temperature controlled bipolar radiofrequency energy (RF) inside the renal artery. See News for more information...

Vessix Vascular is now part of Boston Scientific Corp

Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology for the treatment of hypertension has been acquired by Boston Scientific Corporation (NYSE: BSX).

Vessix is located in Laguna Hills, California and has developed a novel radiofrequency balloon catheter technology for the treatment of uncontrolled hypertension via percutaneous renal denervation. Our product, the V2 Renal Denervation System is now CE-marked (Europe) and TGA (Australia) approved for treating hypertension. The V2 System promises to greatly simplify the renal denervation procedure by employing an efficient and effective novel RF balloon catheter specifically designed for this clinical application. The Company recently completed its pilot human clinical study and is enrolling patients at over 24 centers around the world in a 120 patient (post-market approval) clinical study for the treatment of uncontrolled hypertension. Vessix products are not cleared for sale in the United States.